Radcliffe Department of Medicine

Sharma Group: Mechanistic T Cell Genomics

Our research team is focused on uncovering the mechanisms that govern T cell signaling, with the goal of precisely engineering immune cells for immunotherapies.

Antanaviciute Group: Computational Biology and Tissue Immunology

Rijal Group

Zimmermann Group: Iron Nutrition - Stable Isotopes and Therapeutics

The overall aim of our research program is to improve iron nutrition and reduce anaemia in women and children, directly supporting the U.N.'s 2030 Sustainable Development Goal of ‘Zero Hunger’.

Koohy Group: Machine Learning and Integrative Approaches in Immunology

We would like to understand the functional and molecular mechanisms of the immune system in various immunologically important conditions such as cancer, infection, autoimmune disease as well as ageing. We have a special interest in computational cancer immunotherapy such as antigen presentation, neo-antigen identification and T cell recognition of neo-antigens as well as interrogating the immune response to personalized vaccines from neo-antigens.

Wilkinson Group: Blood Stem Cell Expansion and Fitness

Haematopoietic stem cells (HSCs) support blood cell production throughout life and are also used clinically in cell and gene therapies. We are studying the biology of this important stem cell population with the aim of developing new HSC-based therapies.

Simmons Group: Intestinal Immunity in Health and Disease

We define how the immune system functions in the intestine to promote health. We uncover the immune pathogenesis of intestinal diseases such as inflammatory bowel disease to develop better ways to treat these disorders.

Chakraverty Group: Haematopoietic Transplantation and Immunotherapy

Our group is interested in developing novel immunotherapeutic approaches for leukaemia. Clinical approaches currently used include allogeneic haematopoietic stem cell transplantation, chimeric antigen receptor T cell therapy and immune checkpoint inhibitors. While each of these approaches can be successful, they also fail in many patients as a result of tumour adaptations or diminished function of immune cells. Enhanced immunity can also lead to immune-related adverse events due to on- or off-target effects. We are exploring the mechanisms that underpin these failures and using this information to devise new strategies that can be translated into early phase clinical trials.

Psaila Group: The tumour microenvironment in blood cancers

We focus on four key areas: (1) Dissecting how blood cancers create 'self-reinforcing' niches that promote clonal expansion and protect malignant clones from immunotherapies; (2) Development and application of human bone marrow organoids to study normal and malignant haematopoiesis and validate targets in a relevant tissue microenvironment; (3) Developing novel strategies to selectively target cancer stem cells and pathological megakaryocytes in myelofibrosis, a severe bone marrow malignancy; (4) Understanding our recent discovery that platelets contain a repertoire of DNA fragments sequestered from cell free DNA, and confirming clinical utility for cancer detection and for pre-natal diagnosis.

Davies Group: Genomics and Clinical Genome Editing

We are primarily interested in understanding how the genome functions and to leverage this to develop novel genome editing based cellular therapies

Patel Group: Two tier protection and metabolic genotoxicity during blood production

We study endogenous DNA damage caused by metabolites and their impact on the function of vertebrate stem cells and the ageing process

Chapman Group: Recombination mechanisms in immunity and cancer

Sims Group: Computational Genomics

We are a computational biology research group using genomic and functional genomic data to study transcriptional regulation, with projects spanning from neuroscience to musculoskeletal biology.

Sauka-Spengler Group: Gene Regulatory Networks in Development and Disease

We focus on systems level “big picture” approaches to understand gene regulation and build gene regulatory networks during development and disease in zebrafish, chick, lamprey and human models.

Townsend Group: Molecular Immunology

Jackson Group: Lymphatic Trafficking Research Group

We focus on the mechanisms controlling the migration of leucocytes and tumour cells via lymph in health and disease.

de Bruijn Group: Developmental Haematopoiesis

We study the embryonic origins of blood stem cells with the aim to inform the generation of these cells in culture, and ultimate produce clinically relevant blood stem cells for therapeutic purposes.

Higgs Group: Laboratory of Gene Regulation

We use state-of-the-art laboratory and computational approaches to understand how mammalian genes are switched on and off during development and differentiation and how this goes awry in human genetic diseases.

Davis Group: T-cell Biology

We are interested in how lymphocytes decide to mount immune responses against, for example, tumours. This involves trying to understanding how leukocyte receptors, such as the T-cell receptor and immune checkpoints, are triggered.

Mead Group: Normal and Malignant Haematopoietic Stem Cell Biology

The Mead Lab pioneers research into myeloid neoplasms using cutting-edge single-cell genomics and multiomics to uncover novel therapeutic targets. Our ultimate goal is to translate discoveries from the lab through to patient benefit, including interaction with industry and clinical trials. We foster a collaborative and dynamic environment for innovative science, with a focus on career development for members of the team.

Search results

Found 29 matches for